Amphastar Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 10, 2022, details the results of the Annual Meeting of Stockholders held virtually by Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). The filing covers the voting outcomes for director elections, auditor ratification, and executive compensation.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance data.
Material Changes and Voting Results
Three key proposals were submitted to stockholders, all of which were approved:
- Election of Directors: Three Class III director nominees were elected to serve until the 2025 annual meeting.
- Jack Yongfeng Zhang: 31,356,354 votes For; 6,968,191 votes Against.
- Richard Prins: 28,273,064 votes For; 10,046,064 votes Against.
- Diane Gerst: 25,594,041 votes For; 12,729,425 votes Against.
- Ratification of Auditor: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 42,659,628 For; 696,578 Against.
- Executive Compensation: The compensation of named executive officers was approved on an advisory basis.
- Votes: 37,248,485 For; 1,247,234 Against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting the mechanics and results of the shareholder vote.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (Jack Yongfeng Zhang, Richard Prins, and Diane Gerst) through the 2025 annual meeting.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2022 fiscal year.
- Note the significant number of "Against" votes for director Diane Gerst (12.7 million) compared to the other nominees, which may warrant monitoring of shareholder sentiment.
- Review the company's subsequent 10-K or 10-Q filings for the financial metrics absent from this 8-K.